- Home
- MARA vs RNA Comparison
MARA vs RNA Comparison
Compare MARA & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARA
- RNA
- Stock Information
- Founded
- MARA 2010
- RNA 2012
- Country
- MARA United States
- RNA United States
- Employees
- MARA N/A
- RNA N/A
- Industry
- MARA EDP Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- MARA Technology
- RNA Health Care
- Exchange
- MARA Nasdaq
- RNA Nasdaq
- Market Cap
- MARA 3.7B
- RNA 3.4B
- IPO Year
- MARA N/A
- RNA 2020
- Fundamental
- Price
- MARA $15.76
- RNA $27.87
- Analyst Decision
- MARA Buy
- RNA Strong Buy
- Analyst Count
- MARA 12
- RNA 12
- Target Price
- MARA $20.95
- RNA $68.25
- AVG Volume (30 Days)
- MARA 39.8M
- RNA 1.4M
- Earning Date
- MARA 05-08-2025
- RNA 05-08-2025
- Dividend Yield
- MARA N/A
- RNA N/A
- EPS Growth
- MARA N/A
- RNA N/A
- EPS
- MARA N/A
- RNA N/A
- Revenue
- MARA $705,064,000.00
- RNA $8,927,000.00
- Revenue This Year
- MARA $51.33
- RNA N/A
- Revenue Next Year
- MARA $18.19
- RNA $135.33
- P/E Ratio
- MARA N/A
- RNA N/A
- Revenue Growth
- MARA 40.57
- RNA N/A
- 52 Week Low
- MARA $9.81
- RNA $21.51
- 52 Week High
- MARA $30.28
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- MARA 63.19
- RNA 45.31
- Support Level
- MARA $12.63
- RNA $25.58
- Resistance Level
- MARA $14.96
- RNA $33.62
- Average True Range (ATR)
- MARA 0.93
- RNA 2.09
- MACD
- MARA 0.17
- RNA -0.29
- Stochastic Oscillator
- MARA 88.92
- RNA 28.53
About MARA Marathon Digital Holdings Inc.
MARA Holdings Inc leverages digital asset compute to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.